Evaluation of treatment response by Hopkins criteria on18F FDG PET-CT in patients of non-small cell lung cancer and its comparison with PERCIST response criteria

被引:0
|
作者
Dang, Shreya [1 ]
Shivdasani, Divya [1 ]
Pereira, Melvika [1 ]
Singh, Natasha [1 ]
Rungta, Rachita [1 ]
Roy, Debdip [1 ]
Kesariya, Jugal [1 ]
机构
[1] PD Hinduja Natl Hosp & Med Res Ctr, Dept Nucl Med & PET CT, Veer Savarkar Marg, Mumbai 400016, India
关键词
evaluation; FDG PET; Hopkins; NSCLC; PERCIST; response; POSITRON-EMISSION-TOMOGRAPHY;
D O I
10.1097/MNM.0000000000001756
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim To assess treatment response on FDG PET-CT in NSCLC patients by visual Hopkins score compared to PERCIST criteria and its potential for prognostication (or its correlation with survival).Methods Forty-four NSCLC patients with baseline and post-treatment FDG PET-CT scans were included, and interpreted using Hopkins and PERCIST criteria classifying patients into responders and non-responders. PERCIST-based CMR and PMR, and Hopkins Scores 1,2,3 were classified responders. PERCIST-based SD and PD and Hopkins scores 4,5 were classified as non-responders. Patients were followed upto 24 months after treatment completion. Cohen kappa for inter-criteria agreement and Kaplan Meir curve for overall survival (OS) analysis done.Results Out of 44 patients, PERCIST classified 27 (61.3%) as responders and 17 (38.6%) as non-responders, whereas Hopkins classified 12 patients (27.3%) as responders and 32 (72.7%) as non-responders. Inter-criteria agreement was low (kappa=0.19) with discordance in 45.5% of patients. Eighteen of 20 discordant cases were non-responders on Hopkins and responders on PERCIST, of which 88.8% were non-responders on follow-up as predicted by Hopkins. PERCIST responders had OS of 96.4% and 64.3% at 9 and 24 months, respectively, while non-responders OS was 93.5% and 40.2% at 9 and 24 months, respectively (P-value = 0.049). However, responders on Hopkins had OS of 100% at 24 months, whereas non-responders had OS of 93.5% and 51.5% at 9 and 24 months, respectively (P-value = 0.232).Conclusion Semi-quantitative PERCIST and visual Hopkins criteria show low inter-criteria agreement, with visual criteria better-predicting survival in patients of NSCLC.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 50 条
  • [31] Comparison of EORTC criteria and PERCIST for FDG PET/CT response evaluation of patients with metastatic breast cancer treated with a first line of systemic therapy
    Depardon, E.
    Kanoun, S.
    Humbert, O.
    Riedinger, J.
    Lasserre, M.
    Toubeau, M.
    Berriolo-Riedinger, A.
    Dygai-Cochet, I.
    Fumoleau, P.
    Brunotte, F.
    Cochet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S266 - S266
  • [32] Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan
    F Fathinul
    N Abdul Jalil
    Cancer Imaging, 14 (Suppl 1)
  • [33] The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
    Ozgul, Mehmet Akif
    Kirkil, Gamze
    Seyhan, Ekrem Cengiz
    Cetinkaya, Erdogan
    Ozgul, Guler
    Yuksel, Mahmut
    MULTIDISCIPLINARY RESPIRATORY MEDICINE, 2013, 8
  • [34] Comparison of EORTC, PERCIST, PeterMac & Deauville PET Response Criteria after Radical ChemoRT in Non-Small-Cell Lung Cancer
    Turgeon, G.
    Iravani, A.
    Akhurst, T.
    Callahan, J.
    Cole, A.
    Bressel, M.
    Everitt, S.
    Siva, S.
    Ball, D.
    Mac Manus, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1875 - S1876
  • [35] Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET
    Hoekstra, CJ
    Hoekstra, OS
    Stroobants, SG
    Vansteenkiste, J
    Nuyts, J
    Smit, EF
    Boers, M
    Twisk, JWR
    Lammertsma, AA
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (10) : 1304 - 1309
  • [36] Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment
    Huang, Yubao
    Yang, Yunkai
    Qu, Aidong
    Li, Sixiu
    Chen, Dandan
    Zou, Hongxia
    Li, Songsong
    Zhang, Yaowen
    Zhuang, Wei
    Su, Jing
    Zhou, Xu
    Zhang, Yuntao
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (01) : 101 - 108
  • [37] What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
    Turgeon, Guy-Anne
    Iravani, Amir
    Akhurst, Tim
    Beaulieu, Alexis
    Callahan, Jason W.
    Bressel, Mathias
    Cole, Aidan J.
    Everitt, Sarah J.
    Siva, Shankar
    Hicks, Rodney J.
    Ball, David L.
    Mac Manus, Michael P.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (03) : 328 - 334
  • [38] Role of SFRP5 in Non-Small Cell Lung Cancer and Its Correlation with SUV of 18F-FDG PET-CT
    Zhang, Na
    Bai, Tian
    Jiang, Yunfei
    Zhu, Kun
    Yao, Lan
    Ji, Jia
    Huang, Qicheng
    JOURNAL OF INVESTIGATIVE SURGERY, 2024, 37 (01)
  • [39] Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer
    Julian Kirchner
    Lino M. Sawicki
    Felix Nensa
    Benedikt M. Schaarschmidt
    Henning Reis
    Marc Ingenwerth
    Simon Bogner
    Clemens Aigner
    Christian Buchbender
    Lale Umutlu
    Gerald Antoch
    Ken Herrmann
    Philipp Heusch
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 437 - 445
  • [40] Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer
    Kirchner, Julian
    Sawicki, Lino M.
    Nensa, Felix
    Schaarschmidt, Benedikt M.
    Reis, Henning
    Ingenwerth, Marc
    Bogner, Simon
    Aigner, Clemens
    Buchbender, Christian
    Umutlu, Lale
    Antoch, Gerald
    Herrmann, Ken
    Heusch, Philipp
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (02) : 437 - 445